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Previewsboth BRAF and RAS mutant cells. Struc-
tural analysis revealed that LY3009120
could occupy both protomers in a RAF
dimer and that it was selective for the
inactive, ‘‘DFG-out’’ kinase conforma-
tion, designating it a type II inhibitor.
The accessibility of the ATP binding
pocket allowed by this conformation
may explain how this and other type II in-
hibitors, including BGB659 described
above and two recently reported RAF in-
hibitors (Girotti et al., 2015), can bind
both protomers with similar affinity.
It is clear that the path forward for
more effective RAF therapies will require
drugs that can inhibit both monmeric
and dimeric RAF (Figure 1). Moreover, in-
hibitors that target all RAF members
may expand their use to tumors with up-
stream pathway activation. Determining
the efficacy of these drugs in patients
as well as the potential mechanisms ofdrug resistance will be critical. For the
first generation BRAF inhibitors, drug
resistance has often involved RAF dimer-
ization. However, now, with compounds
that can inhibit RAF dimers, what mech-
anisms will tumor cells use to evade
death? Will mutations that disable
inhibitor binding, such as gatekeeper
mutations, now be observed? Only time
will tell.REFERENCES
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NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use inmul-
tiplemyeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bonemarrow,
are well tolerated, and produce promising response rates when infused after stem cell transplantation.Multiple myeloma (MM) is the second
most common hematological malignancy
characterized by the presence of a mono-
clonal immunoglobulin, clonal plasma
cell (PC) proliferation, bone lesions, hy-
percalcemia, anemia, and/or renal failure.
MM treatment has improved in the
last 15 years with the introduction of
immunomodulatory drugs (IMIDs) and
proteasome inhibitors and, more recently,
monoclonal antibodies (MoAbs) and
HDAC inhibitors, among others (Ocio
et al., 2014). Although such improvements
prolong patients’ survival, MM is still
incurable, and more effective treatments
are needed. The efficacy of immunothera-peutic strategies in solid and hematologic
tumors has stimulated their investigation
in MM.
Several lines of evidence support a role
for immunotherapy in MM. The first
comes from the well-established efficacy
of allogeneic stem cell transplantation
and donor-lymphocyte infusions. The
second is the activity of IMIDs alone or
in combination with other drugs. The third
is the possibility to delay the progression
of high-risk smoldering MM patients by
increasing tumor surveillance of their
‘‘not-so-impaired’’ immune system with
IMIDs (Mateos et al., 2013). The fourth
is that long-term survival of MM patientsis associated with active immune sur-
veillance (Pessoa de Magalha˜es et al.,
2013). Vaccination combining different
antigen formats and adjuvants has also
been investigated in MM (Rosenblatt
et al., 2013), but active vaccine strategies
are restricted by the insufficient numbers
of induced T cells, their poor homing to
tumor sites, and the immunosuppressive
tumor microenvironment. The strategy of
isolating tumor infiltrating lymphocytes
(TILs), expanding them in vitro, and then
transferring them back to the patient
has also been investigated (Noonan
et al., 2015). Notwithstanding, the low
frequency of anti-tumor T cells remains aptember 14, 2015 ª2015 Elsevier Inc. 281
Figure 1. Gene Modification of Peripheral Blood Lymphocytes
CAR T cells expressing on their surface a single-chain including the variable region of a monoclonal antibody (scFv) specific for a surface tumor antigen linked in
tandem to the CD3z chain of the TCR complex and the endodomain of costimulatory molecules are not restricted by the HLA of the patient. Genetically modified
TCR T cells express ab TCRs incorporated with an epitope that recognizes a tumor antigen. The therapeutic potential of TCR T cells depends on their affinity and
avidity for the tumor derived T cell epitope. Several strategies have been developed to generate TCR with increased affinity for tumor antigens, most of them for
HLA-A*0201 restriction (expressed in almost 50% of Caucasians). It is important to note that a TCRwith supra-physiologic affinity might have an increased risk to
damage normal tissues that physiologically express the same target antigen even at a negligible level (on-target toxicity) or cross-react with an unrelated protein
(off-target toxicity).
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Previewsmajor shortcoming for this approach,
which has pushed researchers to modify
T cells to increase their efficacy against
therapeutic targets.
It is now possible to harness effector
T cells with chimeric antigen receptors
(CARs) able to recognize tumor mem-
brane antigens or with T cell receptors
(TCR) that recognize unique tumor pep-
tides presented by major histocompati-
bility complex (MHC) molecules (Figure 1)
(Rosenberg and Restifo 2015). Such
modified T cells can be expanded
in vitro while retaining their potential to
recognize and lyse tumor cells. Both
CAR and TCR T cells have some advan-
tages and limitations (Rosenberg and
Restifo 2015). CAR T cells are not
restricted by the human leukocyte antigen
(HLA) of the patient, but selecting the
appropriate antigen is critical to prevent
off-target toxicity. Many potential targets
used for CAR T cell immunotherapy in
MM have broad normal tissue distribu-
tion, therefore requiring careful evalua-
tion. Moreover, there is risk of a massive
release of pro-inflammatory cytokines
produced by hyperactive CAR T cells.282 Cancer Cell 28, September 14, 2015 ª20Geneticallymodified TCR T cells are redir-
ected by the integration of genes encod-
ing conventional ab TCRs that incorpo-
rate a particular epitope that recognizes
a tumor antigen. Different from CAR
T cells, TCR-engineered T cells recognize
antigens presented by specific HLAmole-
cules and, accordingly, only a limited
number of individuals presenting such
HLA molecules are eligible for this treat-
ment option. However, TCR (but not
CAR) T cells can recognize intracellular
proteins, providing a broader array of
potential therapeutic targets. Engineered
T cells with affinity-enhanced TCRs spe-
cific for various tumor antigens have
been tested in melanoma or gastrointes-
tinal carcinomas with encouraging overall
response rates (Robbins et al., 2015). Un-
til now, there was no promising data re-
ported in MM.
Rapoportetal. (2015) recentlydescribed
the results of 20 MM patients included
in a phase I/II trial designed to assess
the safety and efficacy of NY-ESO-1-
and LAGE-1-specific TCR-engineered
T cells. TCR-engineered T cells were
infused on day +2 after autologous15 Elsevier Inc.stem cell transplant (ASCT), conditioned
with high dose melphalan (HDM; 140–
200 mg/m2) and followed by lenalidomide
maintenance in 13 of 20 cases. Among
the 20 patients, 6 were newly diagnosed,
while the remaining 14 were relapse/re-
fractory (median of 3 prior lines of ther-
apy). At the time of infusion, only 3 pa-
tients were in very good partial response
(VGPR) or better, 6 were in PR, 6 showed
stable disease (SD), and 5 had progres-
sive disease (PD). With the HDM/ASCT
plus infused TCR-engineered T cells
approach, 14 of 20 patients achieved at
least near complete response (nCR), 2
cases attained VGPR, and the other 2
PR (only one SD and one PD). All patients
in PD prior to ASCT achieved nCR or bet-
ter at day +100 after HDM and T cell infu-
sion. Interestingly, 9 patients improved
their depth of response from day +42 to
day +100, though this is something that
can also be seen with HDM/ASCT alone.
Deep responses were also observed in
the 7 patients with high-risk cytogenetics,
but these patients usually respond well
to standard induction therapies, although
with short duration. Overall, responses
Cancer Cell
Previewswere durable, and median progression-
free survival (PFS) of the whole series
was 19.1 months. However, it is not
easy to dissect the specific contribution
of the TCR-engineered T cells from
HDM or from lenalidomide maintenance,
and only a randomized trial will provide
a definitive answer. In particular, it would
be important to know the value of lenali-
domide in both T cell persistence and
duration of response. Apparently, no cor-
relation is observed between these three
parameters. Treatment was well-toler-
ated, particularly when compared with
CAR T cell immunotherapies, with only
mild symptoms of cytokine-release syn-
drome. However, it is possible that
ASCT side effects mask some symptoms
(Rapoport et al., 2015).
One of the most interesting observa-
tions of the present study is the long-
term persistence of affinity-enhanced
T cells (9 of 10 cases reaching 2 years).
Notwithstanding, the numbers of NY-
ESO-1- and LAGE-1-specific TCR-engi-
neered T cells in bonemarrow and periph-
eral blood (PB) progressively decreased
from the moment of infusion; furthermore,
it is not clear whether such T cells main-
tain their functionality over time. These
findings could be of paramount impor-
tance, because progression in 8 of 10
cases correlated with a disappearance
of engineered T cells in PB; conversely,
there were no relapses among antigen-
positive patients showingR6 gene-modi-
fied T cells per microliter in PB. Thus,
in vivo persistence of engineered T cells
and their correct trafficking to tumor
sites are critical for the efficacy of adop-tive cell therapy (ACT). Selection of
T cells with optimal functionality and pro-
liferative capacity, protocols for in vitro
T cell expansion with different cytokine
cocktails, and incorporation of genes
encoding for costimulatory molecules
or cytokines may offer opportunities to
improve ACT based therapies (Rosenberg
and Restifo 2015).
The study reported by Rapoport et al.
(2015) will push forward the role of
immunotherapy in MM. The promising
response rates obtained with HDM/
ASCT plus TCR-engineered T cell infusion
should stimulate the MM scientific com-
munity to build upon these observations.
In particular, high-throughput protein
and sequencing analyses should be
used to not only quantify antigen-specific
T cells and oligoclonal T cell expansions,
but also to determine their functionality
and location within the tumor microenvi-
ronment (Tumeh et al., 2014). Such in-
depth monitoring may be critical to opti-
mize patients’ treatment based on individ-
ual protein-expression-profiles that could
alert the need of complementary treat-
ment with IMIDs or checkpoint inhibitors
to improve the persistence and function-
ality of these cells. On the other hand,
sensitive monitoring of patients’ response
will be required to accurately measure not
only tumor depletion but also normal PC
recovery, and to track clonal heterogene-
ity and tumor escape of antigen-negative
MM cells. Such tumor escape could be
potentially overcome by targeting more
than one antigen, which could also in-
crease the overall applicability of this ther-
apeutic approach (only one-third of theCancer Cell 28, Sepatients screened expressed NY-ESO-1
and/or LAGE-1). The study by Rapoport
et al. (2015) therefore opens new thera-
peutic opportunities to MM patients.REFERENCES
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